

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



-3- * -

(11) Publication number : 0 440 373 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : 91300554.2

(51) Int. Cl.⁵ : C12N 5/08, A61K 35/14

(22) Date of filing : 24.01.91

(30) Priority : 25.01.90 US 471934

(43) Date of publication of application :
07.08.91 Bulletin 91/32

(84) Designated Contracting States :
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant : Bristol-Myers Squibb Company
345 Park Avenue
New York, N.Y. 10154 (US)

(72) Inventor : Ledbetter, Jeffery A.
306 Northwest 113th place
Seattle, Washington 98177 (US)

(74) Representative : Jones, Alan John et al
CARPMAELS & RANSFORD 43 Bloomsbury
Square
London, WC1A 2RA (GB)

(54) Method of activating cytolytic activity of lymphocytes using anti-CD28 antibody.

(57) The development of cytolytic activity of lymphocytes can be potentiated by contacting the lymphocytes with antibody reactive with CD28 receptor, such as 9.3 monoclonal antibody. The cytolytic activity thus potentiated is CD3 heteroconjugate-independent since targeting with a CD3 anti-target compound is not required. The development of cytolytic activity can be further potentiated by also contacting the lymphocytes with antibody reactive with anti-CD2 antibody or immobilized antibody to the CD3 receptor, or by also contacting the lymphocytes with interleukin-2. The CD28 receptor may be aggregated on the surface of the lymphocytes, as by crosslinking the antibody reactive to it on the surface of the lymphocytes. This crosslinking can be by the use of a second antibody reactive with the anti-CD28 antibody. Another aspect of the present invention is a method of adoptive therapy for treating cancer in a subject comprising the steps of: (1) contacting lymphocytes *in vitro* with an antibody reactive with CD28 receptor to potentiate the development of cytolytic activity of the lymphocytes to produce lymphocytes having cytolytic activity that is CD3 heteroconjugate independent; and (2) introducing the cytolytic lymphocytes into a subject to kill cancer cells.

EP 0 440 373 A1

METHOD OF ACTIVATING CYTOLYTIC ACTIVITY OF LYMPHOCYTES USING ANTI-CD28 ANTIBODY

FIELD OF THE INVENTION

This invention relates to methods for potentiating cytolytic activity of lymphocytes, and more specifically to the use of anti-CD28 antibody reactive with receptors on the surface of lymphocytes.

BACKGROUND OF THE INVENTION

One of the promising methods of therapy for cancer is immunotherapy, in which leukocytes, particularly lymphocytes, are stimulated to attack tumor cells. One such method is known as adoptive immunotherapy, in which lymphocytes are stimulated *in vitro* by interleukin-2 (IL-2) to grow and become cytolytic and are then reintroduced into the organism to fight the tumor cells. (Rosenberg et al., *Science* 223 :1318-1321 (1986)).

Methods are known for stimulating lymphocytes to attack tumor cells. For example, CD3-positive T cells can be targeted to lyse tumor cells using heteroconjugates prepared by linking monoclonal antibodies (mAbs) to CD3 and a mAb reactive with a tumor-associated target cell antigen, after incubation with anti-CD3 mAb or with IL-2. (Jung et al., *Proc. Nat. Acad. Sci. (U.S.A.)* 83 : 4479 (1986); Jung et al., *Proc. Nat. Acad. Sci. (U.S.A.)* 84 : 4611 (1987); Titus et al., *J. Immunol.* 138 :4018 (1987); Perez et al., *J. Immunol.* 137 :2069 (1986); Perez et al., *Nature* 316 : 354 (1985)). Likewise, heteroconjugates consisting of anti-CD3 and anti-viral mAbs have been described that induce specific lysis of virus-infected cells (Zarling et al., *J. Immunol.* 140 :2609 (1988); Staerz, et al. *Eur. J. Immunol.* 17 :571 (1987)). These cytolytic cells are referred to as "CD3-dependent" because they require contact with the CD3 receptor to stimulate lytic activity. Specificity of CD3-dependent lysis can also be conferred by conjugating a hormone, such as melanocyte-stimulating hormone, to an anti-CD3 mAb (Liu et al., *Science* 239 :395 (1988)).

Activated T-cells have been reported to be lytic to tumor cells without requiring stimulation of CD3 using Phytohemagglutinin (PHA) stimulation of NK-depleted T cells, or IL-2 stimulation of purified T cells. (Thiele, et al. *J. Immunol.* 140 :3253 (1988); Calamonici et al., *J. Immunol.* 140 :2527 (1988); Damle et al., *J. Immunol.* 137 :2814 (1986); Moriyama et al., *Cell. Immunol.* 111 :482 (1988)). A natural killer (NK)-like activity of CD3⁺ T-cell clones and leukemic cells has also been observed. (Binz et al., *J. Exp. Med.* 157 :1252 (1983); Hercend et al., *Nature* 301 :158 (1983); Irie et al., *Human Immunol.* 11 :183 (1984); Brooks et al., *J. Immunol.* 138 :1331 (1987); Roberts et al., *Eur. J. Immunol.* 15 :448 (1985)). The killing generated after activation is not restricted by the major histocompatibility complex (MHC) and is directed to multiple tumor targets (Thiele et al., *supra*; Calamonici et al., *supra*; Damle et al., *supra*). Such killing is not dependent on CD3 interaction with the tumor cells but may require surface expression of the CD3 T-cell receptor complex (CD3/Ti). (Thiele, et al. *supra*). This killing is referred to as "CD3-independent" lytic activity.

It would, therefore, be desirable to find a novel and efficient method of stimulating T-cells to develop CD3-independent cytolytic activity to attack tumor cells.

SUMMARY OF THE INVENTION

Accordingly, the present invention provides a method for potentiating the development of cytolytic activity of lymphocytes to produce cytolytic lymphocytes by contacting the lymphocytes with antibody reactive with CD28 receptor on the surface of the lymphocytes. The cytolytic activity generated by stimulation of the lymphocytes is CD3 heteroconjugate-independent because the activity does not require stimulation of the CD3/Ti receptor complex, and therefore does not require the use of heteroconjugates containing antibody reactive with the CD3-Ti receptor complex.

The antibody reactive with CD28 receptor is typically a monoclonal antibody. The monoclonal antibody can be an IgG2a antibody, such as monoclonal antibody 9.3.

The method further includes the step of contacting the lymphocytes with a second antibody reactive with CD2 receptor or with CD3 receptor. The second antibody reactive with the CD3 receptor must be immobilized to a solid support. The method can also further comprise the step of contacting the lymphocytes with interleukin-2 (IL-2).

For maximum cytolytic response, the CD28 receptor is aggregated on the surface of the lymphocytes. The CD28 receptor can be aggregated on the surface of the lymphocytes by crosslinking the antibody reactive with CD28 on the surface of the lymphocytes, for example using a second antibody reactive with the antibody reactive with the CD28 receptor. The second antibody can be a rat monoclonal antibody binding to mouse K light

chains, such as monoclonal antibody 187.1. CD28 receptor aggregation can also be induced by a high molecular weight conjugate, for example containing anti-CD28 antibody bound to anti-CD28 antibody, such as 9.3 monoclonal antibody bound to 9.3 monoclonal antibody, (9.3 X 9.3) or by use of immobilized anti-CD28 antibody. The lymphocytes can additionally be contacted with IL-2.

Another important aspect of the present invention is a method for treating cancer in a subject. The method comprises the steps of:

(1) contacting lymphocytes in vitro with an antibody reactive with CD28 receptor to potentiate the development of CD3 heteroconjugate-independent cytolytic activity of the lymphocytes to produce cytolytic lymphocytes; and

(2) introducing the cytolytic lymphocytes into a subject to kill cancer cells in the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is graphs showing treatment of CD16 mAb plus C' to NK cells activated by six methods tested for their ability to lyse in the presence of anti-CD3 (G19-4)/L6 heteroconjugate (□—□), unconjugated G19-4 and L6 (○—○), or alone (●—●), as described in the Example, infra.

Figure 2 is graphs showing the results of treating T-cells with increasing concentrations of IL-2 in the presence of an anti-CD3 mAb (G19-4)/L6 heteroconjugate (□—□), unconjugated mAb G19-4 and L6 (○—○) or alone (●—●) as described in the Example infra.

DETAILED DESCRIPTION OF THE INVENTION

In order that the invention herein described may be more fully understood, the following detailed description is set forth.

The present invention provides a method of stimulating lymphocytes to kill tumor cells using anti-CD28 mAb reactive with the lymphocyte receptor CD28. Although it is believed that agents such as IL-2, anti-CD2 mAb or immobilized anti-CD3 mAb must be present when the T_H cells are originally stimulated by the anti-CD28 mAb to induce the cytolytic activity, it has been found, unexpectedly, that lymphocytes can be efficiently stimulated to attack and lyse tumor cells by contact with anti-CD28 mAb in the absence of CD3 heteroconjugates during the killing or "effector" phase of the lysis. The activity is not inhibited by anti-CD3 mAb. This cell lysing activity stimulated by the contact of T-cell lymphocytes with anti-CD28 antibody is referred to herein as "cytolytic activity". The cytolytic activity stimulated by anti-CD28 mAb is defined herein as "CD3 heteroconjugate independent" during the cell killing phase because a heteroconjugate containing an antibody reactive with the CD3 receptor on T cells and an antibody reactive with tumor-associated antigen for targeting to the tumor cells is not required during this phase.

1. General Stimulation Methods

In general, the development of cytolytic activity can be stimulated by contacting the lymphocytes with anti-CD28 antibody, preferably in the presence of small amounts of IL-2, or in the presence of anti-CD2 or immobilized anti-CD3 antibody. Preferably, the lymphocytes are T-cell lymphocytes. The anti-CD28 antibody can be a polyclonal antibody or a monoclonal antibody, but is preferably a monoclonal antibody. A particular example of such a preferred monoclonal antibody is the monoclonal antibody designated as monoclonal antibody 9.3, ATCC No. 10271 described further infra. Preparation of hybridomas producing monoclonal antibody reactive with a specific receptor such as CD28 receptor are known in the art. Methods such as those described by Kohler and Milstein (Nature 256 :496 (1975)) may be used to produce the hybridomas.

2. Potentiation of the Response by Interleukin-2

Alternatively, the development of cytolytic activity of lymphocytes contacted with anti-CD28 antibody can be further potentiated by treatment with a lymphokine such as IL-2 which is known to stimulate the IL-2 receptor thus activating tyrosine kinase in T cells (Saltzman et al. J. Biol. Chem. 263 :6956 (1988); and Morla et al. Mol. Cell. Biol. 8 :2214 (1988)). When IL-2 is used, it is preferably present at from about 20 units/ml to about 100 units/ml, most preferably at about 50 units/ml.

3. Contact with CD3 or CD2 Antibody

5 The development of cytolytic activity in lymphocytes contacted with anti-CD28 antibody can be further potentiated by contacting the lymphocytes with a second antibody reactive with CD2 receptor or CD3 receptor. Preferably, the second antibody reactive with CD2 receptor or CD3 receptor is a monoclonal antibody. A particular example of a preferred monoclonal antibody reactive with the CD2 receptor is the monoclonal antibody designated as 9.6. described further, infra. A particular example of a preferred monoclonal antibody reactive
10 with the CD3 receptor is the monoclonal antibody designated as G19-4 described further, infra.

Preferably, the antibody reactive with the CD3 receptor is attached to a solid support for presentation to the lymphocytes for induction of cytolytic activity. Suitable solid supports include sepharose beads, or other supports well known in the art. The antibody may be attached to the solid support using standard techniques.

15 4. Crosslinking

The effectiveness of the development of the cytolytic activity by anti-CD28 antibody may be increased by aggregating the CD28 receptors in the cell membrane. Such aggregation can be accomplished by crosslinking the anti-CD28 antibody, i.e. reacting the anti-CD28 antibody with a binding partner on the surface of the lymphocytes. The crosslinking may be accomplished by contacting the anti-CD28 antibody with a second antibody
20 reactive with the anti-CD28 antibody. An example of such crosslinking is the use of a rat monoclonal antibody binding to mouse K chains such as monoclonal antibody 187.1, described infra, as the second antibody. Alternatively, the CD28 receptors may be aggregated by using a higher molecular weight conjugate of anti-CD28 antibody, for example an anti-CD28/anti-CD28 (9.3 x 9.3) homoconjugate. In addition, the T cells may be con-
25 tacted with anti-CD28 antibody immobilized to a plastic surface to aggregate the CD28 receptors on the cell surfaces.

5. Therapy

30 Anti-CD28 mAb is useful to activate lymphocytes in vitro and therefore, may be used to regulate cellular immune responses in diseases, infection, cancer, AIDS and autoimmune disorders. Anti-CD28 mAb may be especially useful for the regulation of cellular immune responses in disease states where there is a defect or dysregulation of T cells.

The present invention encompasses methods for treating lymphocytes in vitro with anti-CD28 mAb for the
35 regulation of cellular immune responses in disease states. According to one embodiment of the invention, anti-CD28 antibody may be used for the in vitro activation of T cells. This activation can be carried out by contacting T lymphocytes taken from a patient with mAb CD28 in vitro whereby the T cells become activated and can then be reinfused into the autologous donor to kill tumor cells as described by Rosenberg et al., supra. Any of the methods of the invention for potentiating the T-cell cytolytic activity using anti-CD28 mAb may be used as the
40 first step in this general method of adoptive therapy. Thus, immobilized anti-CD3 mAb, or anti-CD2 antibody or IL-2 may be added with the anti-CD28 antibody to the lymphocytes in vitro to achieve induction of cytolytic activity in the lymphocytes. The CD28 receptor on the lymphocytes is preferably aggregated to enhance the induction of cytolytic activity, for example by crosslinking the anti-CD28 mAb using a second antibody such as 187.1, or with a second anti-CD28 mAb. Alternatively, the anti-CD28 mAb may be immobilized to a plastic sur-
45 face to aggregate the CD28 receptor for induction of the cytolytic activity. This method of treatment may also involve the in vitro co-incubation or pre-incubation of the T cells with other immunomodulators such as IL-2.

Adoptive therapy has the advantage of avoiding the use of a relatively bulky agent such as a targeting heteroconjugate incorporating an antibody reactive with an antigen associated with a tumor cell. Such heteroconjugates are time consuming and may be difficult to prepare. In adoptive therapy, the lymphocytes
50 are activated in vitro and only the activated lymphocytes are introduced into the subject to kill tumor cells or treat immune disease.

In general, lymphocytes may be activated in vitro for use in adoptive therapy of a patient by treating 10³ to 10⁸ lymphocytes with anti-CD28 mAb added at 100 ng/ml of culture fluid to 1 µg/ml. The activated lymphocytes may then be administered to the patient. The most effective mode of administration and dosage regimen
55 for the adoptive therapy will depend on the severity and course of the disease, the patient's health and response to treatment and the judgement of the treating physician. Accordingly, the dosages of the activated lymphocyte should be titrated to the individual patient.

Th following examples are presented to illustrate the present invention and to assist one of ordinary skill in making and using the same. The examples are not intended in any way to otherwise limit the scope of the disclosure or the protection granted by Letters Patent hereon.

Example5 Activation of Cytolytic Activity With Anti-CD28 AntibodyMonoclonal Antibodies

Anti-CD3 mAb G19-4, ATCC No. HP 9536, an IgG1, was obtained as described in Ledbetter et al., J. Immunol. 136 :3945 (1986). Anti-CD2 mAb 9.6, ATCC No. HB 10267, an IgG2a, was obtained as described in Martin et al., J. Immunol. 131 :180 (1983). Anti-CD28 mAb 9.3, ATCC No. HB 10271, an IgG2a, was obtained as described in Hansen et al., Immunogenetics 10 :247 (1980). Rat mAb 187.1, which binds to mouse K chain, was obtained as described in Yelton et al., Hybridoma 1 :5 (1981). Monoclonal antibody L6, ATCC No. HB 8677, an IgG2a, is broadly reactive with carcinomas and was used for targeting to tumor cells to provide heteroconjugates. It was obtained as described in Hellstrom et al., Cancer Research 46 :3917 (1986). L20, ATCC No. HB 8913, an IgG1 monoclonal antibody, was not reactive with the H3347 carcinoma cell line used as the target and was used as a control in some experiments. All of these mAbs were purified from ascites fluid before use. Anti-CD16 mAb FC-1, an IgM, was obtained as described in Tetterso et al., Leukocyte Typing III, Ch. M5.3, Michael, Ed. (1987), and was used as ascites fluid at a dilution of 1 :100. Anti-CD2 mAb 9-1, an IgG3, was obtained from Dr. B. Dupont (Memorial Sloan Kettering Cancer Center, N.Y.) as described in Yang et al., J. Immunol. 137 :1097 (1986), and was used in purified form. Phorbol-12-myristate-13-acetate (PMA) was obtained from Sigma Chemical Co. (St. Louis, MO).

Preparation of Heteroconjugates

Heteroconjugates were prepared, using maleimidobutyryloxy-succinimide (GMBS ; Calbiochem, La Jolla, CA) and imminothiolane HCl (2-IT, Pierce Chemical Co., Rockford, IL) according to a procedure similar to mAb-Phycoerythrin coupling which has been described by Hardy et al., in Methods in Immunology, D. Wein, Ed., p. 31.1 (1986) and was designed to result in little, if any, unconjugated antibody. Briefly, one mAb was treated with 2-IT at 250 µg/ml mAb and a second mAb was treated with GMBS at 7 µg/ml mAb. The derivitized mAbs were desalted and mixed together to form a stable thioether bond. Heteroconjugates were analyzed by size exclusion chromatography using a Superose-6 (Pharmacia, Uppsala, Sweden) column (1 X 30 cm). Heteroconjugate sizes ranged from >760 kilodaltons (Kd) to 150 Kd (free antibody). The anti-CD3/L6 mAb heteroconjugate targeting activity was present in all fractions containing conjugates (>150 Kd) and was similar in activity to unfractionated heteroconjugate. Therefore, the anti-CD3/L6 heteroconjugate was used unfractionated in the present experiments.

Preparation of Effector Cells

Human peripheral blood mononuclear cells (PBMCs) were separated from the blood of normal, healthy donors by centrifugation over a Ficoll-Hypaque (Organon Teknica Co., Durham, NC) gradient. After being washed twice in culture medium (CM, RPMI 1640 (Gibco, Grand Island, NY) + 1% L-glutamine + 1% Pen/Strep), cells were incubated at 10⁷/ml with anti-CD16 mAb FC-1 in the form of ascites fluid diluted 1 :100 in CM + 15% heat-inactivated pooled normal human serum (PHS) (Pel-Freeze, Brown Deer, WI) for 30 min at 4°C. Rabbit complement (Pel-Freeze) was added at a final dilution of 1 :4, and cells were incubated for 45 min at 37°C. For CD3 activation, 75 cm² flasks were incubated for 60 min at room temperature with 3 ml phosphate buffered saline (PBS) + 10 µg/ml anti-CD3 mAb G19-4. After 3 washings of the flasks, PBMC samples in CM with 10% PHS were added to the flasks which were then incubated at 37°C. Twenty-four hours before assay, the cells were washed and transferred to fresh flasks with or without addition of IL-2 (Genzyme, Boston, MA). Cells were returned to the incubator until use.

CD2 activation was performed either by a two-epitope method of CD2 stimulation (Yang et al., supra) with two anti-CD2 mAbs, 9.6 and 9-1, or by crosslinking mAb 9.6 on the cell surface with the rat anti-mouse K mAb 187.1. CD28 activation was performed in a similar manner by crosslinking mAb 9.3 on the cell surface with mAb 187.1.

Preparation of Target Cells

H3347, a human colon carcinoma line, and H2981, a human lung carcinoma line, were both developed at Oncogen (Seattle, WA). H3347 is a line that is not lysed by stimulation of T cells with an IgG1 anti-CD3 mAb alone, thus avoiding Fc receptor mediated targeting. They were kept in continuous culture in IMDM_c (Iscoe's

Modified Dulbecco's Medium (GIBCO, Grand Island, New York) until use. SS, a B-lymphoblastoid cell line (B-LCL) (Oncogen, Seattle, WA) generated by Epstein-Barr Virus (EBV) transformation of normal cells, and K562, an erythroleukemia line, (Oncogen, Seattle, WA) were kept in continuous culture until use. Target cells (3×10^6) were labeled with 250 μ Ci of ^{51}Cr for 60 min at 37°C and washed 3 times before use.

^{51}Cr Release Assay

The ^{51}Cr release assay measures the cytolytic effect of the effector cells and is described by Jung et al., Proc. Natl. Acad. Sci. USA 83 :4479 (1986). Washed effector cells in 50 μ l CM + 10% PHS ($10^7/\text{ml}$) were added in triplicate to the wells of a 96-well round bottom plate along with 50 μ l CM + 10% PHS, with or without heteroconjugates, antibodies, or various mixtures of the two. Subsequently, the plates were placed in the incubator at 37°C in a 5% CO_2 atmosphere for 4-6 hours. After centrifugation of the plates (400 X g, 10 min), 100 μ l of supernatant were removed from each well. The ^{51}Cr released from lysed cells was determined using a gamma-ray counter (ICN-Micromedex, Worsham, PA). Percent cell-mediated lysis (CML) was calculated by:

$$\frac{(X - \text{SPONTANEOUS RELEASE})}{(\text{MAXIMAL RELEASE} - \text{SPONTANEOUS RELEASE})} \times 100$$

where X is the total release of ^{51}Cr in the presence of the effector cells. Spontaneous release was determined by counting supernatants from labeled target cells incubated only with medium. Maximal release was estimated by exposing labeled target cells to detergent (4% Cetrimide, Sigma Chemical Co., St. Louis, MO) and counting the supernatants. Means of the triplicate determinations are presented herein. Standard errors of the mean did not exceed 10% in any assay. Maximal release averaged 12 times higher in cpm than spontaneous release throughout these experiments.

Depletion of NK Activity by Treatment with Anti-CD16 Antibody Plus Activated Complement

In order to confine the cytolytic activity studied to that of T-cells, CD16-positive cells were removed from PBMCs as a way to eliminate most of the NK cell activity before activating the remaining PBMCs by incubation with immobilized anti-CD3 and IL-2. For this purpose the monoclonal antibody FC-1 (Oncogen, Seattle, WA), an IgM-anti-CD16 mAb that fixes complement efficiently, was used.

The H3347 colon carcinoma cell line, which expresses a surface antigen defined by mAb L6, was labelled with ^{51}Cr and used as targets at an E:T of 50:1 in a five house assay. PBMCs were used as effector cells, either untreated or pretreated with anti-CD16 mAb (FC-1) plus complement (C'). Subsequently, the cells were incubated for 3 days with an anti-CD3 mAb, G19-4, bound to plastic, followed by one day of rest in a fresh flask to which 50 U/ml of IL-2, but no anti-CD3 mAb, had been added. mAb heteroconjugates were used at 3 $\mu\text{g}/\text{ml}$ final concentrations and mAb mixtures were used at 1.5 $\mu\text{g}/\text{ml}$ for each mAb. Table 1 shows the results in percent CML. The data is representative of six experiments.

TABLE 1

Lysis of H3347 Carcinoma Cells by an Anti-CD3 L6 Heteroconjugate

mAb Heteroconjugate or Mixture

Effector Cell Pre- Treatment	Effectors Alone	Anti- CD3/L6	Anti- CD3/ L20	Anti- CD28/ L6	Anti- CD3+L6	L6 Alone
None	21	42	24	18	24	30
Anti-CD16 + C'	1	14	2	1	2	1

Resting PBMCs that had been treated with FC-1 plus C' were not at all cytolytic (0% lysis) when tested against the NK-sensitive line K562 at effector cell/target cell (E:T) ratios of from 12.5:1 to 100:1, while a sample of the same PBMCs that had not been treated with FC-1 lysed the K562 target cells (58% lysis). When the CD16-negative cells were activated by anti-CD3 antibody, no lytic activity of effectors alone was generated, whereas effector cells not treated with anti-CD16 and complement retained their lytic activity (Table 1). However, when a conjugate between mAb L6 and the anti-CD3 mAb G19-4 was added to the H3347 carcinoma cells used as targets, these were lysed by activated CD16 negative PBMCs. Addition of unconjugated mAb in equal amounts did not mediate cytotoxicity. Therefore, lysis of H3347 cells was not dependent upon Fc-mediated targeting by the anti-CD3 mAb used in these experiments. Furthermore, the heteroconjugate effect was CD3-independent, because a conjugate between the L6 mAb and the anti-CD28 mAb 9.3 did not mediate target cell killing. Heteroconjugate targeting was also dependent on the specificity of the tumor-cell antibody, L6, since a heteroconjugate of G19-4 mAb and L20, a mAb reactive with lung carcinomas but negative with H3347, did not induce cytotoxicity.




Activation of CD3 Heteroconjugate-Independent Cytolytic Activity by Stimulation with Anti-CD28 Antibody, Anti-CD2 Antibody and Anti-CD3 Antibody

CD16-negative PBMCs were activated over a 3 day period according to six methods before being tested for their ability to lyse ⁵¹Cr labeled H3347 cells (effector to target cell ratio of 50:1) in a 5 hour assay. Activated cells were tested alone with CM + 10% human serum as a control (●●), with unconjugated mAbs anti-CD3 (G19-4) plus mAb L6 (○○), or with G19-4/L6 heteroconjugate (□□). The results are shown in Figure 1. When cultured without activation (Figure 1A) the cells progressively lost their ability to lyse targets in the presence of the G19-4/L6 heteroconjugate so that by day 3, less than 10% CML was observed. With the donor used for this experiment, activation by anti-CD2 antibody (9.6 + 9-1, Figure 1C) or anti-CD28 (9.3 crosslinked by 187.1, Figure 1D) pathways also failed to activate a heteroconjugate-dependent lysis, although the PBMCs enlarged and entered the cell cycle. Alternatively, activation with anti-CD3 antibody attached to a solid phase increased the cells' CD3-dependent lytic potential over the 3 day period (Figure 1B), generating over 30% CML by day 3 in the presence of heteroconjugate, while there was no killing in the absence of heteroconjugate.

Addition of anti-CD28 mAb 9.3 to either the anti-CD3 activation (Figure 1E) or the anti-CD2 activation (Figure 1F) not only increased heteroconjugate mediated killing by day 3 (anti-CD3 activated cells increased from 32% to 45%; anti-CD2 activated cells increased from 10% to 46%), but also exhibited an increased (20%) CD3 heteroconjugate-independent cytolytic activity. These data suggested separate pathways for the CD3 heteroconjugate-dependent and CD3 heteroconjugate-independent lysis. In 7 costimulation experiments with anti-CD3 mAb, anti-CD28 mAb significantly increased CD3 heteroconjugate-independent cytolytic activity (p < .005). Similarly, in 13 costimulation experiments with anti-CD2 mAb, anti-CD28 mAb significantly increased

CD3 heteroconjugate-independent cytolytic activity ($p < .0005$).

5 Activation of CD3-Independent Cytolytic Activity By Stimulation With IL-2

CD16-negative PBMCs were incubated for 4 days alone, or in the presence of increasing concentrations of IL-2, immobilized anti-CD3 mAb, or a combination of the two. Activated cells were tested for their ability to lyse ^{51}Cr -labeled H3347 tumor targets. Samples were tested in the presence of 3 $\mu\text{g/ml}$ anti-CD3 L6 heteroconjugate (, 3 $\mu\text{g/ml}$ MAb anti-CD3 plus L6 () or alone () and were observed to generate high levels of CD3 heteroconjugate-independent cytolytic activity (Figure 2). At 1000 U/ml of IL-2, lysis in the presence and absence of the heteroconjugate was 77% and 60% respectively. Lysis was not blocked in this experiment by the addition of 3 $\mu\text{g/ml}$ anti-CD3 antibody. In other experiments concentrations of anti-CD3 mAb up to 100 $\mu\text{g/ml}$ were not able to block this IL-2 generated T-cell killing. Even at low levels of IL-2 (10 U/ml), lysis increased from 2% to 20%. When IL-2 was combined with immobilized anti-CD3 during the activation of resting T-cells, the CD3 heteroconjugate-independent cytolytic activity was reduced. When at 1000 U/ml IL-2, effector cells alone gave only 22% CML, while heteroconjugate-mediated lysis remained high (70%). Additionally, four times as many cells were recovered from the groups activated with anti-CD3 + IL-2 as compared to the groups activated with IL-2 alone. Therefore, CD3-heteroconjugate independent cytolytic activity is induced by IL-2 alone, and is decreased rather than increased by immobilized anti-CD3 mAb.

Comparison of IL-2 and Anti-CD28 Antibody Stimulation of CD3-Independent Cytolytic Activity

CD3 heteroconjugate-independent cytolytic activity was induced by stimulating the CD16-negative cells with increasing concentrations of IL-2 and with anti-CD28 antibody by crosslinking mAb 9.3 on the cell surface with mAb 187.1, as described further below. In addition, CD16-negative cells were stimulated with anti-CD28 and anti-CD2 antibody or PMA.

CD16-negative PBMCs were cultured for 4 days alone or in the presence of 1 $\mu\text{g/ml}$ anti-CD28 mAb (mAb 9.3 crosslinked with mAb 187.1), 1 $\mu\text{g/ml}$ anti-CD2 (mAb 9.6 crosslinked by 187.1) or a combination of the two. Co-stimulation of CD2 and CD28 was performed using crosslinking conditions (as described by Ledbetter et al., *E.J. Immunol.* 18 :1601 (1988)). Briefly, 1 $\mu\text{g/ml}$ of mAb 9.3 was combined with 1 $\mu\text{g/ml}$ of mAb 9.6, then 10 min. later with 8 $\mu\text{g/ml}$ mAb 187.1 with no cell wash. Other samples were activated with PMA (10 ng/ml) or a mixture of anti-CD28 mAb and PMA. IL-2 (50 U/ml) was added in some cultures as indicated. Effector cells were incubated in triplicate with ^{51}Cr -labeled H3347 colon carcinoma cells at an E:T ratio of 50:1, alone or in the presence of 1.5 $\mu\text{g/ml}$ each of G19-4 mAb (anti-CD3) and L6 mAb. Percent CML in a 5 hour assay is shown in Table 2. The standard errors of the mean did not exceed 10% in any sample.

TABLE 2
CD28 Stimulation Synergizes with CD2 or PMA
Stimulation in Inducing CD3-Independent Cytolytic
Activity

<u>Induction of Effector Cells</u>		<u>%CML</u>		
<u>mAb and/or PMA</u>	<u>IL-2 (50 U/ml)</u>	<u>Effectors alone</u>	<u>CD3/L6 HC</u>	<u>CD3+L6 Mixture</u>
None	-	2	21	4
	+	7	26	12
Anti-CD28 (9.3 + 187.1)	-	9	25	14
	+	21	25	27
Anti-CD2 (9.6 + 187.1)	-	0	16	2
	+	7	17	6
Anti-CD2+Anti-CD28 (9.3 + 9.6 + 187.1)	-	35	46	39
	+	36	43	40
PMA	-	0	9	4
	+	9	22	21
Anti-CD28 (9.3)+PMA	-	25	41	33

As shown in Table 2, cells cultured with anti-CD28 antibody slightly increased the CD3 heteroconjugate-independent cytolytic activity (9% versus 2%) slightly above background levels, as did activation with low levels of IL-2 (7% versus 2%). However, co-stimulation with CD28 and IL-2 increased the CD3 heteroconjugate-independent cytolytic activity to 21%. In each of these cases, specific heteroconjugate-mediated lysis was essentially unchanged. Crosslinking of an anti-CD2 mAb, alone or in combination with IL-2, induced only minimal cytolytic activity.

Co-stimulation of CD2 and CD28 generated both CD3 heteroconjugate-dependent (46% CML) and heteroconjugate independent (35% CML) activity, which was not further increased by the addition of IL-2 during the 4 day activation. Addition of PMA to the anti-CD28 mAb increased the generation of both the CD3 heteroconjugate-independent and dependent cytolytic activity, while incubation of cells with PMA alone during activation was ineffective. Addition of IL-2 to PMA during the activation period slightly increased the cells' cytolytic ability.

Table 2 thus shows that anti-CD28 antibody can stimulate a significant amount of cytolytic activity independent of the presence of a CD3 heteroconjugate, that is not inhibited by unconjugated anti-CD3 mAb. This stimulation is further increased by the addition of PMA, IL-2, or anti-CD2 antibody. Co-stimulation of cells with anti-CD28 mAb together with IL-2 or in combination with immobilized anti-CD3 mAb was able to elicit or augment a CD3 heteroconjugate-independent cytolytic response as shown in this example. Incubation of cells with IL-2 alone generated high levels of cytolytic activity which was CD3 heteroconjugate-independent and was not inhibited by anti-CD3 mAb.

Although co-stimulation of T-cells with anti-CD28 mAb has been reported to produce high levels of IL-2 (Martin, et al., *J. Immunol.* 136 :3282 (1986)), the results presented herein demonstrate that incubation with anti-CD28 mAb 9.3 plus low levels of IL-2 (10 units/ml) gave a higher cytolytic response than incubation with IL-2 or anti-CD28 mAb individually, suggesting that the generation of cytolytic activity by exposure to an anti-CD28 mAb may not be mediated by IL-2 production alone. This is also supported by IL-2 vs. CD28 signal transduction differences, and differences in the interaction with anti-CD3 mAb.

The anti-CD28 antibody may thus be used to induce cytolytic activity in lymphocytes in the presence of a co-stimulatory agent such as anti-CD2 mAb, immobilized anti-CD3 mAb or IL-2. In addition, in contrast to heteroconjugate-mediated killing which is dependent on stimulation of the CD3 receptor, the cell-killing phase of the cytolytic activity of lymphocytes stimulated with anti-CD28 mAb occurs in the absence of heteroconjugates containing anti-CD3 mAb and a tumor targeting antibody and does not require stimulation of the CD3 receptor.

As will be apparent to those skilled in the art to which the invention pertains, the present invention may be embodied in forms other than those specifically disclosed above without departing from the spirit or essential characteristics of the invention. The particular embodiments of the invention described above, are, therefore, to be considered in all respects as illustrative and not restrictive. The scope of the present invention is as set forth in the appended claims rather than being limited to the examples contained in the foregoing description.

Claims

1. A method for potentiating the development of cytolytic activity of lymphocytes comprising the step of contacting lymphocytes with an antibody reactive with CD28 receptor on the surface of said lymphocytes to produce cytolytic lymphocytes.
2. The method of claim 1 wherein said lymphocytes are T lymphocytes.
3. The method of claim 2 wherein the cell killing phase of said cytolytic activity does not depend on stimulation of the CD3/Ti receptor complex.
4. The method of claim 1 wherein said antibody reactive with CD28 receptor is a monoclonal antibody.
5. The method of claim 4 wherein said monoclonal antibody is monoclonal antibody 9.3.
6. The method of claim 1 further comprising the step of contacting said lymphocytes with antibody reactive with CD2 receptor.
7. The method of claim 6 further comprising the step of crosslinking said antibody reactive with CD2 receptor.
8. The method of claim 1 further comprising the step of contacting said lymphocytes with antibody reactive with CD3 receptor.
9. The method of claim 8 wherein said antibody reactive with CD3 receptor is immobilized to a solid support.
10. The method of claim 1 further comprising the step of contacting said lymphocytes with interleukin-2.
11. The method of claim 1 wherein said lymphocytes are contacted in vitro with said antibody reactive with CD28 receptor.
12. The method of claim 1 wherein said antibody reactive with CD28 receptor on the surface of said lymphocytes is crosslinked to aggregate said CD28 receptor.
13. The method of claim 12 wherein the cross-linking of said antibody reactive with CD28 receptor is carried out by crosslinking said antibody with a second antibody reactive with said antibody reactive with CD28 receptor.
14. The method of claim 13 wherein said second antibody is a rat monoclonal antibody binding to mouse K chains.

15. The method of claim 14 wherein said rat monoclonal antibody is monoclonal antibody 187.1.
- 5 16. The method of claim 13 wherein said antibody reactive with the CD28 receptor is monoclonal antibody 9.3.
17. The method of claim 12 wherein said crosslinking is carried out by contacting said lymphocytes with a high molecular weight conjugate.
- 10 18. The method of claim 17 wherein said high molecular weight conjugate contains anti-CD28 monoclonal antibody linked to anti-CD28 monoclonal antibody.
19. The method of claim 18 wherein said anti-CD28 monoclonal antibody is 9.3.
- 15 20. The method of claim 1 wherein said CD28 receptor is aggregated in vitro on the surface of said lymphocytes by contacting said lymphocytes with immobilized anti-CD28 monoclonal antibody.
21. The method of claim 13 further comprising the step of contacting said lymphocytes with interleukin-2.
- 20 22. A method for treating cancer in a subject comprising the steps of :
 - (a) contacting lymphocytes in vitro with an antibody reactive with CD28 receptor to potentiate the development of cytolytic activity of said lymphocytes to produce lymphocytes having cytolytic activity that is CD3 heteroconjugate-independent ; and
 - (b) introducing said cytolytic lymphocytes into a subject to kill cancer cells in said subject.
- 25 23. The method of claim 22 wherein said antibody reactive with CD28 receptor is a monoclonal antibody.
24. The method of claim 23 wherein said monoclonal antibody is monoclonal antibody 9.3.
- 30 25. The method of claim 22 wherein step (a) further comprises contacting said lymphocytes, in vitro with antibody reactive with CD2 receptor.
26. The method of claim 22 wherein step (a) further comprises contacting said lymphocytes in vitro with antibody reactive with CD3 receptor.
- 35 27. The method of claim 26 wherein said antibody reactive with CD3 receptor is immobilized to a solid support.
28. The method of claim 22 wherein step (a) further comprises contacting said lymphocytes in vitro with interleukin-2.
- 40 29. The method of claim 22 wherein said CD28 receptor is aggregated in vitro on the surface of said lymphocytes.
30. The method of claim 29 wherein said aggregation of the CD28 receptor is carried out by contacting said lymphocytes with immobilized anti-CD28 monoclonal antibody.
- 45 31. The method of claim 29 wherein the aggregation of said CD28 receptor on the surface of said lymphocytes occurs by crosslinking said antibody reactive with CD28 receptor on the surface of said lymphocytes.
- 50 32. The method of claim 31 wherein the cross-linking of said antibody reactive with CD28 receptor occurs by crosslinking said antibody with a second antibody reactive with said antibody reactive with CD28 receptor.
33. The method of claim 32 wherein said second antibody is a rat monoclonal antibody binding to mouse K chains.
- 55 34. The method of claim 33 wherein said rat monoclonal antibody is monoclonal antibody 187.1.
35. The method of claim 31 wherein said antibody reactive with the CD3 receptor is monoclonal antibody 9.3.
36. The method of claim 31 wherein said crosslinking is carried out by contacting said lymphocytes with a high

molecular weight conjugate.

- 5 37. The method of claim 36 wherein said high molecular weight conjugate contains anti-CD28 monoclonal antibody linked to anti-CD28 monoclonal antibody.
38. The method of claim 37 wherein said anti-CD28 monoclonal antibody is 9.3.
- 10 39. A composition comprising cytolytic lymphocytes produced by contacting lymphocytes with an antibody reactive with CD28 receptor on the surface of said lymphocytes.
40. The composition of claim 39 wherein said lymphocytes are T lymphocytes.
- 15 41. Cytolytic lymphocytes obtainable by contacting lymphocytes with an antibody reactive with CD28 receptor on the surface of said lymphocytes.
42. Cytolytic lymphocytes obtainable by a process defined in claim 41 wherein the cytolytic lymphocytes have cytolytic activity that is CD3 heteroconjugate-independent.
- 20 43. Cytolytic lymphocytes obtainable by a process defined in claim 41 or 42 wherein said lymphocytes are T lymphocytes.
44. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 43 wherein the cell killing phase of said cytolytic activity does not depend on stimulation of the CD3/Ti receptor complex.
- 25 45. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 44 wherein said antibody reactive with CD28 receptor is a monoclonal antibody.
- 30 46. Cytolytic lymphocytes obtainable by a process defined in claim 45 wherein said monoclonal antibody is monoclonal antibody 9.3.
47. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 46, the process further comprising the step of contacting said lymphocytes with antibody reactive with CD2 receptor.
- 35 48. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 47, the process further comprising the step of crosslinking said antibody reactive with CD2 receptor.
49. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 48, the process further comprising the step of contacting said lymphocytes with antibody reactive with CD3 receptor.
- 40 50. Cytolytic lymphocytes obtainable by a process defined in claim 49 wherein said antibody reactive with CD3 receptor is immobilized to a solid support.
- 45 51. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 50, the process further comprising the step of contacting said lymphocytes with interleukin-2.
52. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 51 wherein said lymphocytes are contacted in vitro with said antibody reactive with CD28 receptor.
- 50 53. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 52 wherein said CD28 receptor is aggregated in vitro on the surface of said lymphocytes.
54. Cytolytic lymphocytes obtainable by a process defined in claim 53 wherein said aggregation of the CD28 receptor is carried out by contacting said lymphocytes with immobilized anti-CD28 monoclonal antibody.
- 55 55. Cytolytic lymphocytes obtainable by a process defined in claim 53 wherein the aggregation of said CD28 receptor on the surface of said lymphocytes occurs by crosslinking said antibody reactive with CD28 receptor on the surface of said lymphocytes.

56. Cytolytic lymphocytes obtainable by a process defined in any one of claims 41 to 55 wherein said antibody reactive with CD28 receptor on the surface of said lymphocytes is crosslinked to aggregate said CD28 receptor.
57. Cytolytic lymphocytes obtainable by a process defined in claim 55 or 56 wherein the crosslinking of said antibody reactive with CD28 receptor is carried out by crosslinking said antibody with a second antibody reactive with said antibody reactive with CD28 receptor.
58. Cytolytic lymphocytes obtainable by a process defined in claim 57 wherein said second antibody is a rat monoclonal antibody binding to mouse K chains.
59. Cytolytic lymphocytes obtainable by a process defined in claim 58 wherein said rat monoclonal antibody is monoclonal antibody 187.1.
60. Cytolytic lymphocytes obtainable by a process defined in claim 55 or 56 wherein said crosslinking is carried out by contacting said lymphocytes with a high molecular weight conjugate.
61. Cytolytic lymphocytes obtainable by a process defined in claim 60 wherein said high molecular weight conjugate contains anti-CD28 monoclonal antibody linked to anti-CD28 monoclonal antibody.
62. Cytolytic lymphocytes obtainable by a process defined in claim 61 wherein said anti-CD28 monoclonal antibody is 9.3.
63. A method, for producing cytolytic lymphocytes according to any one of claims 41 to 62, which comprises contacting lymphocytes with an antibody reactive with CD28 receptor on the surface of said lymphocytes.
64. Cytolytic lymphocytes according to any one of claims 41 to 62 for use as a medicament.
65. Use of cytolytic lymphocytes according to any one of claims 41 to 62 for the manufacture of a medicament for the treatment of cancer.
66. A pharmaceutical composition comprising cytolytic lymphocytes according to any one of claims 41 to 62 in combination with a pharmaceutically acceptable carrier, diluent or excipient.
67. A method for making a pharmaceutical composition comprising combining cytolytic lymphocytes according to any one of claims 41 to 62 with a pharmaceutically acceptable carrier, diluent or excipient.
68. A kit for sequential use in potentiating the development of cytolytic activity of lymphocytes to produce cytolytic lymphocytes, the kit comprising :
 a) an antibody reactive with CD28 receptor on the surface of said lymphocytes ;
 b) means for treating the lymphocytes with the antibody.
69. A kit for sequential use in the treatment of cancer in a subject, the kit comprising :
 a) an antibody reactive with CD28 receptor on the surface of lymphocytes ;
 b) means for treating the lymphocytes with the antibody ;
 c) means for introducing the cytolytic lymphocytes into the subject.

Figure 1





Figure 2





European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT
which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

Application number

EP 91 30 0554

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
Y	THE JOURNAL OF IMMUNOLOGY, vol. 140, no. 6, 15th March 1988, pages 1753-1761, The American Association of Immunologists, Baltimore, US; N.K. DAMLE et al.: "Differential regulatory signals delivered by antibody binding to the CD28 (Tp44) molecule during the activation of human T lymphocytes"		C 12 N 5/08 A 61 K 35/14
	* Page 1758, left-hand column, line 23 - page 1760, left-hand column, line 24 *	1-21, 39-69	
	--		
P,Y	EP-A-0 360 205 (S. FUJIMOTO)		
	* Whole document *	1-21, 39-69	
	--		
	./.		
INCOMPLETE SEARCH The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims. Claims searched completely: 1-21, 39-69 Claims searched incompletely: 22-38 Claims not searched: Reason for the limitation of the search: Method for treatment of the human or animal body by surgery or therapy (See art. 52(4) of the European Patent Convention)			
Place of search THE HAGUE		Date of completion of the search 25-04-1991	Examiner NOOIJ
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date O : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO Form 1505.1 (03/82)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application number:

EP 91 30 0554

-2-

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P, X	WO-A-90 05 541 (THE REGENTS OF THE UNIVERSITY OF MICHIGAN) * Page 4, lines 21-28; claims *	1-21, 39-69	
A	PROC. NATL. ACAD. SCI. USA, vol. 84, no. 13, July 1987, pages 4611-4615, Washington, DC, US; G. JUNG et al.: "Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates" * Whole article *	1-21, 39-69	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)